Cytocom, Inc. to Report Second Quarter 2021 Financial Results20210810073000
Cytocom, Inc. to Report Second Quarter 2021 Financial Results
August 10, 2021
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn’s Disease, Hematology, Pancreatic Cancer and COVID-1920210809073000
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs20210805073300
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing20210729073300
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs20210728083000
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger20210706091600
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC20210617183700
Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP53220210414080000
Cleveland BioLabs, Inc. Announces Closing of $14 Million Registered Direct Offering of Common Stock20210223163000
Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock20210219133000